Predict your next investment

Corporation
boehringer-ingelheim.com

See what CB Insights has to offer

Investments

10

Portfolio Exits

7

Funds

1

Partners & Customers

10

About Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company that focuses on prescription medicines, consumer health care, chemicals, biopharmaceuticals, and animal health.

Boehringer Ingelheim Headquarter Location

Binger Strasse 173

Ingelheim am Rhein, 55216,

Germany

+49 - 6132 - 77 0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Boehringer Ingelheim

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Boehringer Ingelheim in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Infectious Disease

2,222 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

D

Digital Therapeutics

341 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

Latest Boehringer Ingelheim News

Boehringer Ingelheim and Amgen collaborate on cancer trial

Sep 17, 2021

17 Sep 2021 (Last Updated September 17th, 2021 10:24) The trial will evaluate the combination of BI 1701963 and Lumakras (sotorasib) in patients with lung and colorectal cancers. Share Article Boehringer Ingelheim and Amgen have entered a clinical phase I collaboration to evaluate a potential combination therapy for cancer. The trial will determine additional therapeutic benefits of using a combination of SOS1::pan-KRAS inhibitor BI 1701963 and Lumakras (sotorasib) in patients living with lung and colorectal cancers. Lumakras (sotorasib) is a KRASG12C inhibitor for adult patients with locally advanced or metastatic non-small cell lung cancer. The therapy was approved by the US Food and Drug Administration (FDA) earlier this year. The move comes after preclinical data suggested that the combination of a KRASG12C inhibitor with a SOS1::pan-KRAS inhibitor may increase anti-tumour activity in KRAS G12C-driven cancers. The data indicates that SOS1::pan-KRAS inhibitors sensitise KRAS G12C-mutant tumours to covalent KRASG12C inhibitors that bind to inactive KRAS. Boehringer Ingelheim Oncology Global Therapy Area Head corporate senior vice-president Francesco Di Marco said: “We are excited to partner with Amgen, who have pioneered KRAS G12C inhibition, and to further expand our programme to make a difference for people living with KRAS-driven cancers. “Boehringer Ingelheim follows an ‘all-in’ research approach to taking cancer on, including the first and most advanced SOS1::pan-KRAS inhibitor, which we investigate in several combinations and cancer types to realise even more opportunities to deliver potential therapeutic benefits to cancer patients.” As agreed, Amgen will sponsor the study while both companies will jointly share the costs of clinical development for the combined therapy. They will also co-supervise the clinical development. Boehringer Ingelheim is a research-driven biopharmaceutical company headquartered in Germany.

Boehringer Ingelheim Investments

10 Investments

Boehringer Ingelheim has made 10 investments. Their latest investment was in T-Knife as part of their Series A on August 8, 2020.

CBI Logo

Boehringer Ingelheim Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/6/2020

Series A

T-Knife

$78.17M

Yes

6

4/15/2019

Corporate Minority

SoundTalks

Yes

1

6/12/2015

Grant - V

National Comprehensive Cancer Network

$2M

No

1

4/13/2015

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

5/22/2014

Grant - IV

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/6/2020

4/15/2019

6/12/2015

4/13/2015

5/22/2014

Round

Series A

Corporate Minority

Grant - V

Partnership

Grant - IV

Company

T-Knife

SoundTalks

National Comprehensive Cancer Network

Subscribe to see more

Subscribe to see more

Amount

$78.17M

$2M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

1

10

10

Boehringer Ingelheim Portfolio Exits

7 Portfolio Exits

Boehringer Ingelheim has 7 portfolio exits. Their latest portfolio exit was ArmaGen on March 27, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/27/2020

Acquired

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/27/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Boehringer Ingelheim Acquisitions

10 Acquisitions

Boehringer Ingelheim acquired 10 companies. Their latest acquisition was NBE Therapeutics on December 10, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/10/2020

Series C

$991

$65.74M

Acquired

4

12/9/2020

Acquired

1

7/27/2020

Acquired

4

5/18/2020

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

7/15/2019

Series B - II

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

12/10/2020

12/9/2020

7/27/2020

5/18/2020

7/15/2019

Investment Stage

Series C

Unattributed VC

Series B - II

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$65.74M

$99M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

4

1

4

10

10

Boehringer Ingelheim Fund History

1 Fund History

Boehringer Ingelheim has 1 fund, including Boehringer Ingelheim Venture Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/31/2010

Boehringer Ingelheim Venture Fund

Early-Stage Venture Capital

$135.3M

1

Closing Date

3/31/2010

Fund

Boehringer Ingelheim Venture Fund

Fund Type

Early-Stage Venture Capital

Status

Amount

$135.3M

Sources

1

Boehringer Ingelheim Partners & Customers

10 Partners and customers

Boehringer Ingelheim has 10 strategic partners and customers. Boehringer Ingelheim recently partnered with GoodRx on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/9/2021

Partner

GoodRx

United States

Boehringer Ingelheim teams up with GoodRx on cost-savings initiative

In related news , GoodRx also recently unveiled a partnership with health information technology firm Surescripts to facilitate physicians ' access to point-of-care drug costs .

1

8/4/2021

Partner

Columbia China

China

Columbia Clinic signed a cooperation agreement with Boehringer Ingelheim

Ms. Tan Bee Lan , President and Group CEO of Columbia China said : '' Our collaboration with Consanas will focus on the following aspects : first , we will leverage on medical resources from both sides and develop in-depth collaborations in talent exchange .

2

8/3/2021

Licensor

Nanoform Finland

Finland

Nanoform and Boehringer Ingelheim execute master services agreement

BC Platforms has signed a partnership with Dartmouth-Hitchcock 's laboratory of Clinical Genomics and Advanced Technology in the Department of Pathology & Laboratory Medicine in the US , focused on providing data management solutions in cancer research .

3

7/23/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/24/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/9/2021

8/4/2021

8/3/2021

7/23/2021

6/24/2021

Type

Partner

Partner

Licensor

Licensor

Partner

Business Partner

GoodRx

Columbia China

Nanoform Finland

Country

United States

China

Finland

Subscribe to see more

Subscribe to see more

News Snippet

Boehringer Ingelheim teams up with GoodRx on cost-savings initiative

In related news , GoodRx also recently unveiled a partnership with health information technology firm Surescripts to facilitate physicians ' access to point-of-care drug costs .

Columbia Clinic signed a cooperation agreement with Boehringer Ingelheim

Ms. Tan Bee Lan , President and Group CEO of Columbia China said : '' Our collaboration with Consanas will focus on the following aspects : first , we will leverage on medical resources from both sides and develop in-depth collaborations in talent exchange .

Nanoform and Boehringer Ingelheim execute master services agreement

BC Platforms has signed a partnership with Dartmouth-Hitchcock 's laboratory of Clinical Genomics and Advanced Technology in the Department of Pathology & Laboratory Medicine in the US , focused on providing data management solutions in cancer research .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

3

10

10

Boehringer Ingelheim Team

8 Team Members

Boehringer Ingelheim has 8 team members, including current Managing Director, John Dixon.

Name

Work History

Title

Status

John Dixon

Managing Director

Current

Simon Sturge

President, Senior Vice President

Former

Robert Berg

Chief Financial Officer

Former

Steffen Saltofte

Merial, The Maersk Group, and Syngenta

Chief Operating Officer

Former

Peter Mueller

Senior Vice President

Former

Name

John Dixon

Simon Sturge

Robert Berg

Steffen Saltofte

Peter Mueller

Work History

Merial, The Maersk Group, and Syngenta

Title

Managing Director

President, Senior Vice President

Chief Financial Officer

Chief Operating Officer

Senior Vice President

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.